Disc Medicine (IRON) Capital Expenditures (2021 - 2025)
Disc Medicine (IRON) posted quarterly Capital Expenditures of $20000.0 for Q4 2025, down 95.55% year-over-year from $449000.0 in Q4 2024, and down 23.08% quarter-over-quarter from $26000.0 in Q3 2025.
Powered by 
Analysis
Disc Medicine (IRON) Capital Expenditures (2021 - 2025) Analysis & Trends
Disc Medicine (IRON) has reported Capital Expenditures for 5 consecutive years, with $20000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Expenditures fell 95.55% year-over-year to $20000.0; the TTM figure through Jun 2026 stood at $46000.0 (down 96.54% YoY), while the FY2025 annual figure was $933000.0, up 84.75% from the prior year.
- Capital Expenditures declined to $20000.0 in Q4 2025 per IRON's latest filing, from $26000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $851000.0 in Q1 2025 and bottomed at -$8000.0 in Q3 2024.
- Historically, Capital Expenditures has averaged $99117.6 across 5 years, with a median of $20000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 14866.67% in 2024 and fell as far as 125.0% in 2024.
- Disc Medicine's Capital Expenditures stood at $7000.0 in 2021, then soared by 71.43% to $12000.0 in 2022, then slumped by 75.0% to $3000.0 in 2023, then jumped by 14866.67% to $449000.0 in 2024, then slumped by 95.55% to $20000.0 in 2025.
- Business Quant data shows IRON's Capital Expenditures at $20000.0 in Q4 2025, $26000.0 in Q3 2025, and $36000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 851,000.00 |
| Dec 31, 2024 | 449,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 19,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 7,000.00 |